Evotec
About: Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Employees: 5,022
0
Funds holding %
of 6,810 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.32% more ownership
Funds ownership: 4.18% [Q2] → 4.5% (+0.32%) [Q3]
14% less funds holding
Funds holding: 28 [Q2] → 24 (-4) [Q3]
17% less capital invested
Capital invested by funds: $35.6M [Q2] → $29.6M (-$5.98M) [Q3]
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8
86%
upside
Avg. target
$8
86%
upside
High target
$8
86%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Douglas Tsao 47% 1-year accuracy 79 / 168 met price target | 86%upside $8 | Buy Reiterated | 7 Nov 2024 |
Financial journalist opinion
Neutral
Seeking Alpha
1 week ago
Evotec: Some Recovery Has Come, But Much More Is Expected
Evotec, a German drug discovery company, has shown strong top-line growth and significant partnerships, but struggles with financial performance and profitability, making it a speculative "Buy". Despite a 20% return since my last article, Evotec's stock remains volatile, with profitability expected around 2025-2026, driven by strong partnerships and strategic initiatives. The company has a solid liquidity position, low debt, and is on track with cost optimizations and strategic reviews, indicating potential for significant upside.
Neutral
Accesswire
4 weeks ago
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases LAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center. LAB eN² is also expanding to include five additional academic institutions: Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai.
Neutral
Accesswire
1 month ago
Evotec Announces Change in Management Board
Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024 Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS.
Neutral
Accesswire
1 month ago
Comment on Withdrawn Non-Binding Offer
HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO) Evotec SE has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ:EVO) ("Evotec") for EUR11.00 per share in cash. The Management Board and Supervisory Board of Evotec, together with its advisors, have been in the process of thoroughly assessing the Non-Binding Proposal submitted by Halozyme in a letter dated 13 November 2024, in which it expressed an interest in a combination of Halozyme with Evotec.
Negative
Reuters
1 month ago
Halozyme withdraws $2.1 bln buyout offer for Evotec
Halozyme Therapeutics said on Friday it had withdrawn its proposal to acquire Evotec SE for 2 billion euros ($2.09 billion) after the German drug developer was unwilling to engage in discussions.
Neutral
PRNewsWire
1 month ago
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
SAN DIEGO , Nov. 22, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. Helen Torley, president and chief executive officer of Halozyme , shared the following statement: "We continue to believe that a combination of Halozyme and Evotec would create a leading, differentiated, global pharma services company, benefitting shareholders, patients and employees.
Positive
Bloomberg Technology
1 month ago
Halozyme CEO: Evotec Is Poised for Growth
Halozyme CEO Helen Torley joins to discuss the company's intended acquisition of biotech company Evotech. She speaks with Caroline Hyde on "Bloomberg Technology.
Neutral
PRNewsWire
1 month ago
Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec
Would establish an innovative pharma services company with capabilities spanning drug discovery and development, biologic manufacturing and drug delivery technologies Would meaningfully diversify, scale and extend Halozyme's revenue and adjusted EBITDA well into the next decade and beyond All-cash transaction would be funded by cash on hand and new debt with expected pro forma net leverage less than 2x two years post close SAN DIEGO , Nov. 18, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided an update on its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. In a presentation posted on its investor relations website, Halozyme highlights how its proposed combination with Evotec would create a leading global innovative pharma services company that would deliver significant value to all stakeholders.
Positive
Benzinga
1 month ago
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion
On Thursday, Halozyme Therapeutics, Inc. HALO submitted a non-binding proposal to Evotec SE EVO to acquire the German company for 11.00 euros per share in cash, implying a fully diluted equity value of 2.0 billion euros (around $2.11 billion).
Neutral
Accesswire
1 month ago
Comment on Media Report
HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
Charts implemented using Lightweight Charts™